|
| |
| |
-
Berger P., Gruschwitz M., Spoetztl G.,
Dirnhofer S., Madersbacher S., Gerth R., Mezr W.E., Plas E., Sampson
N.:
“Human chorionic gonadotropin (HCG)
in the male reproductive tract“
Molecular
and Cellular Endocrinology, 190-196, (260-262), 2007
Normal hypothalamic-pituitary testicular and prostatic functions are
essential for maintenance of male fertility, whereby glycoprotein
hormones (GPH) as well as androgens are major endocrine and local
regulators. We have investigated whether the GPH human chorionic
gonadotropin (hCG) and the free alpha and beta subunits thereof are
produced in the target organs themselves and potentially act as
auto/paracrine modulators of fertility. Immunofluorometric assays (IFMAs)
based on our panel of highly selective monoclonal antibodies,
immunohistochemistry (IHC), confocal laser scanning microscopy (CLSM)
and 1- and 2D gel electrophoreses with subsequent western blotting
have been utilized for the detection of hCGalpha, hCGbeta and its
metabolite hCGbeta core fragment (cf) in human testis, prostate and
seminal plasma. Both organs synthesize hCGalpha and hCGbeta, which
are subsequently detectable at high concentrations in seminal plasma
of healthy probands (n=17): hCGalpha 2630+/-520 ng/mL (mean+/-S.E.M.),
hCGbeta 2+/-0.28 ng/mL, hCGbetacf and hCG 0.19+/-0.039 ng/mL. These
parameters significantly exceed physiological values, e.g. ten
thousand-fold in the case of hCGalpha, in serum of young men (n=20):
hCGalpha 0.142+/-0.054 ng/mL (mean+/-S.E.M.), hCGbeta 0.05 ng/mL and
hCG 0.004+/-0.003 ng/mL. Levels of these markers were not correlated
with sperm counts. Of all body fluids including those of pregnant
women seminal plasma is the richest physiological source for genuine
free i.e. non-dissociated GPHalpha (M(r,app) 23k) which may even
appear as di- or tetramers. Its concentration is similar to that
observed in maternal serum (weeks 10-12 of gestation) and in
extra-embryonic coelomic fluid. In contrast to those fluids where
ratios of free subunits to hCG are in the range of 1:100 highly
inverse ratios in the range of 10.000:1.000:1 were observed for
hCGalpha:hCGbeta:hCG in seminal plasma. hCGalpha is not derived from
heterodimeric GPH suggesting hCG-independent functions of hCGalpha
and hCGbeta in male and female fertility. 
-
Daha L., Lazar D.,
Simak R., Pflüger H.:
“Is there a
relation between urinary interleukin-6 levels and symptoms before
and after intra-vesical glycosaminoglycan substitution therapy in
patients with bladder pain syndrome/interstitial cystitis?“
Int.
Urogynecol J, 18, (1449-1452), 2007
Urinary interleukin-6 (IL-6) has been proposed as a
sensitive and specific inflammatory marker in bladder pain syndrome/interstitial
cystitis (BPS/IC). We therefore investigated the presence of urinary
IL-6 in patients with BPS/IC to find a possible correlation with the
symptoms before and after glycosaminoglycan substitution therapy.
Urinary IL-6 levels of 25 BPS/IC patients were assessed
semi-quantitavely (Milenia Quickline) before and after intra-vesical
glycosaminoglycan substitution therapy. Patients received therapy
twice weekly with 300 mg pentosanpolysulphate for 5 weeks.
Responders were treated for another 5 weeks, whilst non-responders
received 40 mg hyaluronic acid weekly for another 10 weeks instead.
Treatment response was assessed by the visual analogue scale (VAS)
for quality of life and O'Leary-Saint Symptom and Problem Index (OSPI)
before, during the 5th week of the treatment and 1 week after the
treatment. Before treatment, measurable IL-6 was found in urine
samples from 9 out of 25 patients. After treatment, urinary IL-6 was
detected in two patients only. The average VAS and OSPI scores
before the treatment were 7.9 (4-10) and 25.4 (12-37), respectively.
After the treatment, the average VAS and OSPI scores dropped to 5.5
(0-10) and 14.7 (1-29), respectively. No statistically significant
difference was found between patients with and without urinary IL-6
and the VAS and OSPI scores before and after the treatment. The
urinary IL-6 level in BPS/IC patients is neither suited as a
diagnostic marker nor as a predictor of responses to therapies. For
the future, it would be important to clarify whether there are
subsets of patients with diseases of different aetiologies.
-
Daha L., Lazar D.,
Engelhardt P.F., Simak R., Pflüger H.:
“Acupuncture
Treatment of Psychogenic Erectile Dysfunction: A Four-Year Follow-Up
Study“
Curr.Uro., 1, (39-41), 2007
The aim of the study was to assess the longterm effects of
acupuncture treatment in patients suffering from psychogenic
erectile dysfunction (ED). Patients and Methods: Twenty patients
with psychogenic ED who underwent acupuncture treatment between 1999
and 2001 were invited to an after-care interview with the items
International Index of Erectile Function (IIEF) 15 Score, influence
of acupuncture on quality of life, effect and duration of
acupuncture treatment on erectile status and willingness to repeat
the treatment. Results: Fifteen patients accepted our invitation.
Comparison of the IIEF 15 Score shortly after treatment with the
Score in 2005 showed no statistically relevant difference (P =
0.608). Sixty-seven percent (n = 10) of the after-care patients
reported an improvement in their quality of life and 53% (n = 8)
would repeat this acupuncture treatment. Conclusions: The results
are a first indication that long-term effects could be reached
through acupuncture treatment.
-
Plas E., Berger I.:
“Genital
Trauma“
Buch
“Emergencies in Urology”, 2, (260-269), 2007
-
Plas E.:
“Androgensubstitution: wer, wann, wie lange”
CliniCum
Urologie, 4, (8-10), 2007
-
Plas E., Pernkopf
D.:
“Sexualität:
Auch im Alter ein wichtiges Thema“
Geriatrie
Praxis Österreich, 2, (18-20), 2007
-
Daha L., Simak R.:
“Harnleiter-
und Nierenbeckentumore: Diagnostik und Therapie“
Krebshilfe!, 3, (6-7), 2007
-
Stancik I., Plas E.:
“Diagnostik
und Therapie des invasiven Blasenkarzinoms“
Krebshilfe!, 3, (11-12), 2007
-
Plas E.:
“Kinderwunsch: Onkologie und Fertilität“
Urologik,
2, (16-17), 2007
-
Plas
E.:
“Männlicher
Kinderwunsch und Genetik – Was soll der Urologe wissen?“
J.Urol.Urogynäkol., 5, (2-3), 2007
PDF-Volltextartikel
-
Stancik I., Plas E.:
“Neues zum
Harnblasenkarzinom – Diagnostik und Therapie“
Urologik,
2, (16-17), 2007
PDF-Volltextartikel
-
Plas E.:
“Die
Bedeutung der erektilen Dysfunktion“
MEDahead
report, (1-2), 2007
-
Plas E.:
“Höheres
Risiko für Prostatakarzinom bei Testosteron-Behandlung?“
Uroscope,
Juni, (5-6), 2007
-
Plas E.:
“Rauchen
begünstigt Erektionsstörungen“
Ärztekrone,
8, (30-32), 2007
-
Höltl W., Jeschke K., Jungwirth A., Loidl W.,
Plas E., Rauchenwald M., Reiter W., Schatzl G., Schratter-Sehn A.,
Zigeuner R., Reissigl A.:
“Expertise:
PDE-5-Hemmer zur Behandlung nach Prostatektomie“
Österreichische Ärztezeitung, Supplementum 5, (1-4), 2007
-
Plas E., Essl A.:
“Welchen
Stellenwert hat Sexualität für einen Urologen und Patienten in
Abhängigkeit vom Alter“
J.Urol.Urogynäkol., Sonderheft 2, 35, 2007
-
Stancik I., Plas E.,
Daha K., Juza J., Pflüger H.:
“IL-6, IgG,
IgA und Leukozytenzahl-Bestimmung im Seminalplasma/Ejakulat und
Postmasturbationsharn bei Patienten mit einer chronischen
Prostatitis“
J.Urol.Urogynäkol., Sonderheft 2, 39-40, 2007
-
Loidl W., Hobisch
A., Riedl C., Penkoff H., Pflüger H., Jeschke K., Schmeller N.,
Schmidbauer J., Zaack D.:
“Konsensus:
Leitlinien zur Anwendung der Fluoreszenzzystoskopie mit
Hexaminolevulinat beim Harnblasenkarzinom “
Universimed-Verlag, 1-8, 2007
-
Lazar
D.:
“Impact of
BPS/IC (Bladder Pain Syndrome / Interstitial Cystitis) on Sexual
Functions and Partnerships of Female Patients“
Poster,
ausgezeichnet als beste Posterpräsentation am Europ. Kongress für
Sexualmedizin in Lissabon 2007
|
| |
|
|
